Tissue-homing marker expression after allogeneic HSCT. (A) Expression of the gut-homing marker α4β7 by the ILCs of patients with high or low proportions of CD69⁺ ILCs, 12 weeks after allogeneic HSCT. (B) Expression of the gut-homing marker α4β7 in healthy controls (black bars) and patients with and without acute GVHD of the gut. (C) Proportion of CLA⁺ (left panels) and CCR10⁺ (right panels) ILC1 and NCR^– ILC3 in healthy controls (black bars) and patients with and without GVHD of the skin. Data are shown as median values with interquartile ranges and were all taken 12 weeks after allogeneic HSCT (n = 40 [cohort 2, Table 1]). *P < .05, **P < .01, ***P < .001. HC, healthy controls (black bars, n = 8).